Editas' EDIT-101 Set To Be First In Vivo CRISPR Gene-Editing Therapy In Clinic
Executive Summary
Editas CEO says recent IND filing to treat LCA10 eye disease puts EDIT-101 on track to be first CRISPR medicine administered directly to patients. Bosley also voices relief at recent US IP court ruling.
You may also be interested in...
Where Angels Fear To Tread: Lessening The Perils Of CRISPR-Based Therapies
CRISPR is in the headlines once again, but for all the wrong reasons. While germline gene editing remains taboo in legitimate research, it is a reminder that there is much to be learned in ensuring the safety of the technique in general. AstraZeneca has developed a new method which it believes will help avoid off-target effects, an executive explains to In Vivo.
Where Angels Fear To Tread: Lessening The Perils Of CRISPR-Based Therapies
CRISPR is in the headlines once again, but for all the wrong reasons. While germline gene editing remains taboo in legitimate research, it is a reminder that there is much to be learned in ensuring the safety of the technique in general. AstraZeneca has developed a new method which it believes will help avoid off-target effects, an executive explains to In Vivo.
Editas Competitor CRISPR Therapeutics Hails European Patent Decision
CRISPR Therapeutics says its IP position has been reinforced by the European Patent Office's aim to grant the University of California patent recognition covering CRISPR gene-editing for non-cellular and cellular use.